ARBUTUS BIOPHARMA CORP

Arbutus Biopharma insider option buys signal bullish confidence on its hepatitis B pipeline, hinting at a potential rally amid rising social‑media buzz.

Arbutus Biopharma insiders, including CFO Nguyen Tuan, grant significant RSUs and options—showing confidence amid a patent setback and volatile stock, signaling potential upside for investors.